I added an old GPU to my Plex server and it finally stopped buffering ...

"The financing agreement provides TransCode with financial flexibility and ensures that TransCode can maintain operational momentum as we conduct our Phase 2a trial for our lead clinical program, ...

TransCode Therapeutics Inc. (NASDAQ:RNAZ) said it has secured a financing agreement with an institutional healthcare investor that could provide the company with up to $20 million in funding. The ...

TransCode Therapeutics Inc. stock grades by Barron's. View RNAZ fundamental and sentiment analysis powered by MarketGrader.

BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced today it has entered into an exclusive, worldwide, royalty-free license agreement with Unleash Immuno Oncolytics, Inc. to develop three ...

TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer. BOSTON, March ...

The data describe a template-driven RIG-I agonist strategy to selectively activate retinoic acid-inducible gene I (RIG-I) signaling inside tumor cells by leveraging overexpressed oncogenic microRNAs, ...

TransCode Therapeutics ( (RNAZ)) has provided an update. On February 5, 2026, TransCode Therapeutics, in collaboration with Quantum Leap Healthcare Collaborative, announced that it had submitted an ...

Add Yahoo as a preferred source to see more of our stories on Google. The trial aims to assess biological and clinical activity of TTX-MC138 in patients with MRD. Credit: Pickadook / Shutterstock.com.

BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk ...

Glioblastoma is the most aggressive primary brain cancer, with median survival under two years from diagnosis despite current standard-of-care interventions. The molecular target of TTX-MC138, ...